ReNeuron Group plc Director/PDMR Interest in Shares & Share Options (7554F)

TIDMRENE

RNS Number : 7554F

ReNeuron Group plc

17 July 2019

 
 17 July 2019   AIM: RENE 
 

ReNeuron Group plc

Director/PDMR Interest in Shares and Share Options

ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that the following share option grants were made yesterday under the Company's Long Term Incentive Plan (the "Plan") to directors and Persons Discharging Managerial Responsibilities (PDMRs) listed below.

The Plan allows the Company to grant tax-advantaged share options under a Company Share Option Plan (the "CSOP Plan"), as well as non-tax advantaged options. Where capacity exists for a director/PDMR to be issued share options under the CSOP Plan, these options are issued in parallel with non tax-advantaged options. The figures per individual below, where applicable, therefore comprise parallel grants of both CSOP Plan share options and non tax-advantaged share options, the terms of each grant ensuring that the exercise of one type of option reduces the number exercisable under the other type of option on a share for share basis. Individuals can therefore elect, subject to their tax status, which specific option grant (CSOP or non tax-advantaged options) they exercise.

Share options granted under the CSOP Plan are over shares up to an aggregate market value of GBP30,000 (measured at the date of grant) and with an exercise price of 237.5 pence per share, being the closing mid-market price of the Company's shares on 15 July 2019. Non tax-advantaged options are granted at nominal value.

The share options granted to Mr Hellebø and Mr Hunt have been awarded under the Plan in connection with the Company's remuneration policy whereby executive Directors are eligible to earn a non-cash bonus payable in the form of share options based on the achievement of certain objectives in the year to 31 March 2019. In line with the terms of the Plan and the Company's remuneration policy, these share options are exercisable from the second anniversary of the award and are not subject to performance conditions.

The share options granted to Mr Adams are exercisable from the third anniversary of the award and are subject to the achievement of the following performance conditions:

1) When the Company has signed out-licensing deal(s) for any of its technologies or programmes which, together with other financial resources, provides sufficient funding to allow the achievement of clinical proof of concept data for the CTX and hRPC programmes, one third of the options will vest.

2) When the Company's share price has doubled from the price at the date of grant, one third of the options will vest.

3) When the sixth clinical trial of a ReNeuron cell therapy completes, one third of the options will vest.

Share option grants are deemed accepted by the option holder unless expressly rejected within a period of 30 days from the date of grant.

 
 Name                 Title                      Date of                  Total shares    Percentage 
                                                  grant       Number       over which      of issued 
                                                  of share     of share    options         shares 
                                                  options      options     are held        under option 
                                                  (i)          granted     (post award) 
                      VP Business Development     16 July 
   Nicholas Adams       & Alliance Management       2019       77,895        77,895           0.24% 
                     -------------------------  -----------  ----------  --------------  -------------- 
                          Chief Executive         16 July 
 Olav Hellebø             Officer              2019       30,254       1,096,975         3.45% 
                     -------------------------  -----------  ----------  --------------  -------------- 
                          Chief Financial         16 July 
    Michael Hunt               Officer              2019       23,697        576,221          1.81% 
                     -------------------------  -----------  ----------  --------------  -------------- 
 

(i) The option grants are under the non-tax advantaged scheme and (where capacity exists) the CSOP Plan (as detailed above).

The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation and provide further detail.

ENQUIRIES:

 
ReNeuron                                         [phone] 
Olav Hellebø , Chief Executive Officer 
Michael Hunt, Chief Financial Officer 
Buchanan                                         [phone] 
Mark Court, Sophie Cowles, Tilly Abraham 
 
Stifel Nicolaus Europe Limited                   [phone] 
Jonathan Senior, Stewart Wallace, Ben Maddison 
 (NOMAD and Joint Broker) 
N+1 Singer                                       [phone] 
Aubrey Powell, James Moat, Iqra Amin 
 (Joint Broker) 
 
 

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa, and for disability as a result of stroke. ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

(Disclosure in relation to share options granted to Directors and PDMRs)

 
       Details of the person discharging managerial responsibilities 
   1    / person closely associated 
 a)    Name                         Nicholas Adams 
      ---------------------------  ---------------------------------------------- 
 2     Reason for the notification 
      --------------------------------------------------------------------------- 
 a)    Position/status              VP Business Development & Alliance Management 
      ---------------------------  ---------------------------------------------- 
 b)    Initial notification         Initial notification 
        /Amendment 
      ---------------------------  ---------------------------------------------- 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      --------------------------------------------------------------------------- 
 a)    Name                         ReNeuron Group plc 
      ---------------------------  ---------------------------------------------- 
 b)    LEI                          2138003TU12CQ5TZO137 
      ---------------------------  ---------------------------------------------- 
 4     Details of the transaction(s): section to be repeated for (i) 
        each type of instrument; (ii) each type of transaction; (iii) 
        each date; and (iv) each place where transactions have been conducted 
      --------------------------------------------------------------------------- 
 a)    Description of               Ordinary Shares 1p 
        the financial instrument,    RENE - GB00BF5G6K95 
        type of instrument 
        Identification 
        code 
      ---------------------------  ---------------------------------------------- 
 b)    Nature of the transaction    Grant of share options and conditional rights 
      ---------------------------  ---------------------------------------------- 
 c)    Price(s) and volume(s)         Price(s)   Volume(s) 
                                       1p         77,895 
                                                 ---------- 
      ---------------------------  ---------------------------------------------- 
 d)    Aggregated information       N/A 
      ---------------------------  ---------------------------------------------- 
 e)    Date of the transaction      Granted 16 July 2019 
      ---------------------------  ---------------------------------------------- 
 f)    Place of the transaction     Outside a trading venue 
      ---------------------------  ---------------------------------------------- 
 
 
       Details of the person discharging managerial responsibilities 
   1    / person closely associated 
 a)    Name                                    Olav Hellebo 
      --------------------------------------  --------------------------------- 
 2     Reason for the notification 
      ------------------------------------------------------------------------- 
 a)    Position/status                         Chief Executive Officer 
      --------------------------------------  --------------------------------- 
 b)    Initial notification                    Initial notification 
        /Amendment 
      --------------------------------------  --------------------------------- 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      ------------------------------------------------------------------------- 
 a)    Name                                    ReNeuron Group plc 
      --------------------------------------  --------------------------------- 
 b)    LEI                                     2138003TU12CQ5TZO137 
      --------------------------------------  --------------------------------- 
 4     Details of the transaction(s): section to be repeated for (i) 
        each type of instrument; (ii) each type of transaction; (iii) 
        each date; and (iv) each place where transactions have been conducted 
      ------------------------------------------------------------------------- 
 a)    Description of                          Ordinary Shares 1p 

        the financial instrument,               RENE - GB00BF5G6K95 
        type of instrument 
        Identification 
        code 
      --------------------------------------  --------------------------------- 
 b)    Nature of the transaction               Grant of share options 
      --------------------------------------  --------------------------------- 
 c)    Price(s) and volume(s)                    Price(s)   Volume(s) 
                                                  1p         30,254 
                                                            ---------- 
      --------------------------------------  --------------------------------- 
 d)    Aggregated information                  N/A 
      --------------------------------------  --------------------------------- 
 e)    Date of the transaction                 Granted 16 July 2019 
      --------------------------------------  --------------------------------- 
 f)    Place of the transaction                Outside a trading venue 
      --------------------------------------  --------------------------------- 
 
 
       Details of the person discharging managerial responsibilities 
   1    / person closely associated 
 a)    Name                                    Michael Hunt 
      --------------------------------------  --------------------------------- 
 2     Reason for the notification 
      ------------------------------------------------------------------------- 
 a)    Position/status                         Chief Financial Officer 
      --------------------------------------  --------------------------------- 
 b)    Initial notification                    Initial notification 
        /Amendment 
      --------------------------------------  --------------------------------- 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      ------------------------------------------------------------------------- 
 a)    Name                                    ReNeuron Group plc 
      --------------------------------------  --------------------------------- 
 b)    LEI                                     2138003TU12CQ5TZO137 
      --------------------------------------  --------------------------------- 
 4     Details of the transaction(s): section to be repeated for (i) 
        each type of instrument; (ii) each type of transaction; (iii) 
        each date; and (iv) each place where transactions have been conducted 
      ------------------------------------------------------------------------- 
 a)    Description of                          Ordinary Shares 1p 
        the financial instrument,               RENE - GB00BF5G6K95 
        type of instrument 
        Identification 
        code 
      --------------------------------------  --------------------------------- 
 b)    Nature of the transaction               Grant of share options 
      --------------------------------------  --------------------------------- 
 c)    Price(s) and volume(s)                    Price(s)   Volume(s) 
                                                  1p         23,697 
                                                            ---------- 
      --------------------------------------  --------------------------------- 
 d)    Aggregated information                  N/A 
      --------------------------------------  --------------------------------- 
 e)    Date of the transaction                 Granted 16 July 2019 
      --------------------------------------  --------------------------------- 
 f)    Place of the transaction                Outside a trading venue 
      --------------------------------------  --------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

MSCDMGMNGVLGLZZ

(END) Dow Jones Newswires

July 17, 2019 02:00 ET (06:00 GMT)